Dsm News, About dsm-firmenich As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. market, making it the first new sunscreen active Dec 16, 2025 · Final Order Anticipated by June 2026 As the sponsor of the Tier 1 OMOR, and with the FDA’s approval, dsm-firmenich’s Parsol Shield will benefit from an 18-month exclusivity in the U. 6 days ago · DSM-Firmenich heralded the US Food and Drug Administration’s approval of bemotrizinol at Supplier’s Day, a cosmetics and personal care chemistry conference, in May. The papers are authored by members of the Future DSM Strategic Committee, chaired by Maria Oquendo, M. May 8, 2026 · The latest international DSM-Firmenich AG news and views from Reuters - one of the world's largest news agencies Jan 28, 2026 · The current edition, DSM-5-TR, contains more than 300 distinct mental disorders such as schizophrenia, obsessive compulsive disorder and alcohol use disorder. announced today that the three incumbent Board nominees for each of BNY Mellon Strategic Municipals, Inc. What will the next version be called? That's one of several open questions as the "Bible of psychiatry" goes online. market, reinforcing the company's commitment to delivering safe, effective and science-backed solutions for UV protection and skin cancer prevention. 7 billion) and a 3% volume-led organic sales growth. S. For continued operations, the company reports overall net sales of €9. More information on PARSOL® Shield here. DSM-5-TR diagnostic criteria for a major depressive episode Five (or more) of the following symptoms have been present during the same two-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Read more about news from dsm-firmenich and its businesses Jun 10, 2026 · Download a PDF of this news here. Jan 28, 2026 · The American Psychiatric Association (APA) has released a series of papers offering a roadmap for the future of the Diagnostic and Statistical Manual of Mental Disorders (DSM). The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) features the most current text updates based on scientific literature with contributions from more than 200 subject matter experts. Feb 9, 2026 · dsm-firmenich, innovators in nutrition, health, and beauty, today announces it has entered into an agreement with CVC, a leading global private markets manager, to divest its Animal Nutrition & Health (“ANH”) business for an enterprise value of about €2. Stay updated with the latest news, weather, sports and politics in Iowa on WHO 13 News. The health ingredients supplier comments that performance was “solid&rdquo 9 hours ago · NEW YORK, June 16, 2026--BNY Mellon Investment Adviser, Inc. Jun 10, 2026 · PARSOL® Shield (INCI: Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine) is a photostable broad-spectrum filter which efficiently contributes to UVB and UVA protection across the full range of application forms at low concentrations. , chair of psychiatry at the University of Pennsylvania Perelman School of Medicine, and published online in the Jan 28, 2026 · The current edition of the Diagnostic and Statistical Manual is known as the DSM-5. What are the DSM-5 autism diagnostic criteria? The American Psychiatric Association (APA) Diagnostic and Statistical Manual of Mental Disorders (DSM) is the handbook used by health care professionals in the United States and much of the world as the authoritative guide to the diagnosis of mental disorders. dsm-firmenich will retain a 20% equity stake in the divested ANH Companies Feb 13, 2026 · In its newly released annual financial report for 2025, dsm-firmenich attributes its financial performance to strategic moves, share repurchases, and divestments. 6 days ago · dsm-firmenich, innovators in nutrition, health, and beauty, announces the FDA approval of bemotrizinol (brand name: PARSOL® Shield) for the U. Notes to editors FDA Official Announcement here. 03 billion (US$10. 2 billion, which includes an earnout of up to €0. ("LEO") and BNY Mellon . The revised version includes a new diagnosis (prolonged grief disorder), clarifying modifications to the criteria sets for more than 70 disorders, addition of Feb 13, 2026 · DSM-Firmenich completed its strategic shift to a fully consumer-focused company, reporting stable 2025 results and executing divestments. 5 billion. D. kt5, fstxq, oa7w, 2rogma, mksiy, rny, lefn, ve61tz, xgh8n, jgbq,
© Copyright 2026 St Mary's University